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Role of Stat3 in Regulating HIF-1alpha Expression and Tumor Angiogenesis 
Jon Briggs 
ABSTRACT 
 
Increased vascularization (angiogenesis) is a required adaptation for sustained 
tumor growth, and the primary mediator of de novo blood vessel formation is vascular 
endothelial growth factor (VEGF). The central transcriptional activator of VEGF is 
hypoxia inducible factor-1 (HIF-1), a heterodimeric transcription factor composed of an 
inducible HIF-1α subunit and a constitutively expressed HIF-1β subunit. In addition to 
HIF-1, it has recently been reported that signal transducer and activator of transcription 3 
(Stat3) is required for VEGF production and angiogenesis. Although it is known that 
Stat3 is an important mediator of many of the oncogenic signaling pathways that regulate 
HIF-1α, it was not known if Stat3 regulates HIF-1α. To answer this important question, 
the effect of blocking Stat3 signaling on both HIF-1α and VEGF expression was 
examined. Treatment of cells with IL-6, a potent activator of Stat3, resulted in HIF-1α 
and VEGF induction during normoxia. By blocking protein synthesis with 
cycloheximide, it was determined that IL-6 induction of HIF-1α resulted from increased 
translation. When Stat3 was silenced with siRNA, both basal level expression and IL-6 
induction of HIF-1α and VEGF were significantly reduced. Furthermore, it is likely that 
Stat3 is required for HIF-1α induction by a variety of growth signals, as both HIF-1α and  
VEGF expression resulting from EGF and heregulin were abolished when Stat3 signaling 
 x
was blocked. Because we had observed that Stat3 was required for induction of HIF-1α 
by growth signals, we wanted to determine if Stat3 was also required for HIF-1α 
induction by hypoxia. When stat3 was silenced and cells exposed to hypoxia, HIF-1α 
expression was again abolished. Furthermore, the hypoxic induction of VEGF and MMP-
2 was also prevented. These results, along with loss of basal expression of HIF-1α, 
suggest that Stat3 is fundamentally involved with the cellular reponse to hypoxia. This 
idea is reinforced by our observation that Stat3 is activated by hypoxia in several cell 
lines. These findings position Stat3 as an important target for antiangiogenic therapy, not 
only through its direct regulation of the VEGF gene, but also because it is required for 
expression of the other most important transcriptional activator of VEGF. 
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INTRODUCTION 
 
Tumor hypoxia and angiogenesis 
 
As solid tumors grow beyond a diameter of 1-2 millimeters, they outgrow the 
existing blood supply (52). As a result, areas of low oxygen (hypoxia) develop. The 
presence of hypoxic regions was originally hypothesized in response to the observation 
that necrosis increased as distance from the vasculature increased (199). Confirmation of 
this theory, and more accurate measurements of tumor oxygen levels were achieved with 
oxygen electrodes. It was observed that oxygen levels in tumors were highly variable, 
with areas as low as 0.7% OB2B (206). For their continued growth and survival in a hypoxic 
environment, tumor cells encourage growth of new blood vessels from the pre-existing 
vasculature in a process known as angiogenesis (60). It is clear that tumors have an 
absolute requirement for vascularization, and in the absence of angiogenesis, sustained 
tumor growth cannot occur (59, 60, 87, 118).  
In response to hypoxia, cell signaling pathways and transcription factors are 
activated in the tumor cells that help them cope with the harsh tumor microenvironment 
(87). Activation of these pathways results in changes in gene expression encouraging 
survival under conditions of low oxygen, low nutrients, and high acidity. There is 
increased need for glucose uptake and metabolism due to low oxygen and nutrients, and 
as a result there is increased expression of glucose transporters and glycolytic enzymes. 
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Because it is a toxic environment characterized by hypoxia and acidosis, there is elevated 
expression of growth factors and survival pathways. Angiogenesis is facilitated by the 
release of soluble factors such as VEGF that bind to receptors on vascular endothelial 
cells and encourage their migration and growth. Furthermore, factors are released which 
result in the breakdown and restructuring of the extracellular matrix, allowing endothelial 
cell migration. In this manner, tumors restructure the local vasculature to fulfill their need 
for oxygen and nutrients. 
A poor clinical outcome correlates with both microvessel density (118, 216) and 
tumor hypoxia (93). The reason for this is that although many tumors are highly 
vascularized, the tumor vasculature is often poorly formed and inefficient (24). The 
tumor vascular system is characterized by leaky blood vessels, haphazard patterns of 
connections, loose attachment, and an abnormal basement membrane (107). These 
abnormalities result in a tumor environment that although vascularized, is characterized 
by hypoxia, acidosis, and necrosis (107). Tumors with a high degree of hypoxia amount 
to a poor prognosis for patients for a variety of reasons. Cells adapted to hypoxia tend to 
upregulate genes associated with angiogenesis and metastasis (171).  It is clear that 
hypoxia exerts selective pressure for formation of a tumor with greater resistance to 
apoptosis (77). Furthermore, the environment tends to increase mutation rates (232, 233). 
These adaptations result in a tumor with greater potential for survival and metastasis. In 
addition, hypoxic tumors tend to have greater resistance to treatment with drugs and 
radiation (16, 45, 81). The implication is that tumor cell survival is facilitated by both 
encouragement of angiogenesis and adaptation to hypoxia, and therefore tumor 
progression correlates with both hypoxia and vascularization. 
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Antiangiogenic therapy was proposed due to the observation that solid tumors 
require vascularization for sustained growth (60). By preventing growth of new blood 
vessels, the tumor could be deprived of oxygen and nutrients and continued growth 
would be inhibited. It is clear that tumors have an absolute requirement for 
vascularization, and inhibition of angiogenesis can prevent tumor growth (59, 60, 86, 87, 
118). Furthermore, there have been reports of successful clinical trials (115, 226). 
Importantly, it has been reported that antiangiogenic therapy in conjunction with 
radiation and chemotherapy resulted in an improved response (75, 100, 122, 134, 146, 
197). Despite these successful trials, many of the antiangiogenesis inhibitors when used 
alone have not been effective (12, 54). A likely explanation for this is that they were not 
effective enough, as the majority of them have only targeted an individual angiogenic 
factor such as VEGF, and it is known that vascularization is a complex process involving 
a variety of factors (54, 118). When drugs are developed with greater potency that are 
capable of blocking a wide variety angiogenesis inducers, it is likely that clinical trials 
will be more successful either alone or in conjunction with traditional radiation and 
chemotherapy (12, 97).  
 
Vascular Endothelial Growth Factor 
 
It had long been known that tumor cells secrete a factor capable of initiating 
angiogenesis, however the stimulus responsible for its production was not known (53, 
61). Subsequently, it was demonstrated that macrophages exposed to a hypoxic 
environment were shown to secrete an angiogenesis-stimulating factor (124). Vascular 
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endothelial growth factor (VEGF) was then purified, sequenced and cloned, leading to its 
identification and characterization as an exceptionally potent angiogenic mitogen (117, 
135). Following this, it was shown that high VEGF expression occurs close to necrotic 
and presumably hypoxic areas, demonstrating probable in vivo stimulation of 
angiogenesis by a hypoxic environment (187).  
VEGF is a soluble factor capable of stimulating blood vessel growth, and is 
important for processes such as embryogenesis and wound repair (52, 54). Furthermore, 
it is well established that VEGF is an important mediator of tumor angiogenesis and 
progression (53, 84, 151, 162, 187). Tumors with high expression of VEGF have been 
shown to be of increased grade and result in a poor clinical outcome (163, 203, 216). 
VEGF is demonstrated to be an important therapeutic target in both animal models (9, 97, 
101, 103, 121-123, 221, 231) as well as patients (100, 115, 226). It is clear from these 
reports that VEGF is essential for tumor angiogenesis, and inhibition of VEGF can 
prevent angiogenesis and tumor growth. 
The biologically active form of vascular endothelial growth factor is VEGF-A 
(54), usually referred to as VEGF, and it forms a 45 kDa homodimer (55). VEGF 
undergoes splice variation to form four main variants of the protein denoted by subscript 
numbers representing the number of amino acids: VEGFB121B, VEGF B165B, VEGF B189B, and 
VEGF B206 B(96, 202). These different isoforms bind with varying affinities to both the 
extracellular matrix and receptors expressed on most endothelial cells (54). The two 
major VEGF RTKs are VEGF receptor 1 (VEGFR-1, Flt-1) and VEGF receptor 2 
(VEGFR-2, KDR, FLK) (40, 198). Although both of these receptors are upregulated by 
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hypoxia and important for angiogenesis, VEGFR-2 is the primary mediator of the growth 
and angiogenic properties of VEGF (54, 183). 
 
Regulation of VEGF 
 
Regulation of VEGF expression may result from transcriptional, post-
transcriptional or translational mechanisms. Increased transcription results from hypoxia 
or growth signals and is facilitated by transcription factors such as HIF-1 and Stat3. 
Concerning post-transcriptional modification, proteins binding to the 3’-untranslated 
region of VEGF mRNA result in its stabilization in response to hypoxia (31, 36, 136, 
190). Furthermore, VEGF may be regulated at the translational level by a mechanism 
dependent on the PI3K/AKT/mTOR pathway (30, 150). 
In addition to hypoxia (187) and acidosis (185), VEGF transcription can be 
induced by a variety of soluble factors such as growth factors, cytokines, and hormones. 
Examples of these include transforming growth factor-β (TGF-β) (63, 160), tumor 
necrosis factor (TNF) (63, 174), platelet-derived growth factor (PDGF) (56, 209), 
keratinocyte growth factor (KGF) (63), Interleukin-6 (IL-6) (33, 38), hepatocyte growth 
factor (HGF) (235), Interleukin-1β (IL-1β) (139), fibroblast growth factor-2 (FGF-2) (43, 
174)), epidermal growth factor (EGF) (32, 63), and insulin-like growth factor 1 IGF-1) 
(32, 72). Many of these signals are commonly overexpressed by tumor cells, and result in 
paracrine induction of VEGF which is essential for tumor vascularization (84).  
Tumor cells often produce high levels of VEGF without any external stimulation. 
This results from genetic changes undergone by the tumor cells themselves, such as loss 
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of tumor suppressor function and oncogene overexpression. Concerning tumor 
suppressors, loss of von Hippel-Lindau (VHL) gene (102), p53 (120, 154), and 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (238) are 
associated with increased expression of VEGF. In addition to negative regulation by 
tumor suppressors, VEGF is upregulated by a variety of receptor and non-receptor 
tyrosine kinases. Examples of membrane bound TKs capable of increasing VEGF 
production include EGFR (161) and HER2 (133, 161). Various non-receptor TKs also 
stimulate VEGF production, examples include c-SrcP
pp60
P (47, 155, 218), v-Src (109, 154), 
and Ras (83, 166) .  
The best documented signaling pathways capable of stimulating VEGF 
production are PI3K/AKT and the Ras/Raf/MEK/ERK pathway. Many of the growth 
signals or genetic alterations responsible for upregulating VEGF expression are 
dependent on the kinases PI3K and Akt (32, 110, 133, 209). Furthermore, loss of function 
of the tumor suppressor PTEN results in activation of the PI3K/ AKT pathway (85, 189, 
222) and increased VEGF expression (238). Concerning the Ras/Raf/MEK/ERK cascade, 
VEGF is upregulated by mutant Ras (166), v-Ras (83) and v-Raf (83). Furthermore, 
VEGF is required for Ras-mediated tumorigenesis (84).  
Increased transcription of the VEGF gene results from activation of a limited set 
of transcription factors. The VEGF promoter contains several confirmed transcription 
factor binding sites, including HIF-1 (62, 137), Stat3 (159, 214), AP-1 (174), and Sp1 
(56, 174, 184), and AP-2 (69, 202). Induction of VEGF by hypoxia involves HIF-1α, and 
this process is well characterized (137, 140). Furthermore, it has been demonstrated that 
AP-1 becomes activated under hypoxia (173, 227), and possibly contributes to the HIF-1 
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response to hypoxia (1, 35, 130). It has recently been reported that Stat3 and HIF-1α are 
both required for maximal VEGF induction by hypoxia (82). 
 
Other angiogenic factors 
 
Angiogenesis is a complex process requiring not only endothelial cell growth and 
migration, but also processes involving reorganization of the extracellular matrix and 
basement membrane (94). As a result, a variety of factors in addition to VEGF are 
required. Several other factors facilitate angiogenesis in a direct manner by stimulating 
growth of vascular endothelial cells, these include basic fibroblast growth factor (bFGF, 
or FGF-2) (50) and IL-8 (125). Other factors act in an indirect manner by increasing 
VEGF production, and these were described in the previous section. In addition to factors 
that stimulate endothelial cell growth, others have been described that regulate 
angiogenesis in negative manner. An important example of a negative regulator of 
angiogenesis is thrombospondin 1 (TSP-1), which functions by inhibiting endothelial cell 
proliferation and inducing apoptosis (112, 175). Furthermore, as with VEGF, it has been 
reported that many of these factors are regulated in response to hypoxia, including PDGF 
(126, 129), IL-8 (44, 224) and bFGF (129) .   
In addition to endothelial cell migration and growth, angiogenesis requires 
breakdown of the extracellular matrix and basement membranes, allowing endothelial 
cells to migrate toward the source of the angiogenic stimulus. Important factors involved 
in this process are the matrix metalloproteinase enzymes, in particular MMP-2 (gelatinase 
A) and MMP-9 (gelatinase B) (149). It has been demonstrated that MMP-2 is upregulated 
 8
by hypoxia (128), and is important for tumor angiogenesis (104), as well as invasion and 
metastasis (95, 104, 178). 
  
Hypoxia inducible factor 
 
Hypoxia inducible factor 1 (HIF-1) was originally described as a transcription 
factor that binds to the 3’-enhancer of the erythropoietin (EPO) gene, a protein important 
for synthesis of haemoglobin, upregulating its production in response to hypoxia (182). It 
rapidly became apparent that this transcription factor was instrumental in the hypoxic 
regulation of cellular processes beyond haemoglobin synthesis, as the enhancer sequence 
was still responsive in cells incapable of producing EPO (211). Furthermore, it was 
discovered that a common transcriptional complex inducible by hypoxia was involved 
with the regulation of a variety of angiogenic factors (71, 73, 140, 181). The 
demonstration that HIF-1 was required for VEGF induction by hypoxia confirmed the 
importance of HIF-1 in the cellular response to hypoxia (62). A number of subsequent 
studies confirmed that HIF-1 was induced by hypoxia and facilitated transcription of an 
array of genes essential for angiogenesis (165). 
Hypoxia inducible factor is a heterodimeric transcription factor composed of an 
alpha and beta subunit (210, 212). Both subunits belong to a family of transcription 
factors which contain a basic-helix-loop-helix (bHLH) and Per/Arnt/Sim (PAS) domain 
(210), sequences important for dimerization and DNA binding. The HIF-1β subunit, also 
known as aryl hydrocarbon nuclear transporter (ARNT), dimerizes with multiple 
members of the bHLH-PAS family of TFs (145). Although both subunits are for the most 
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part continuously transcribed, HIF-1α is rapidly degraded under hypoxia and is subjected 
to extensive post-translational regulation. On the other hand, HIF-1β is constitutively 
expressed and is not subject to regulation by hypoxia (99). Following translocation to the 
nucleus, HIF-1 binds to promoters of genes containing hypoxia response elements and 
increases their transcription (180) (Figure 1). 
The alpha subunit exists in three isoforms, HIF-1α, HIF-2α, and HIF-3α. The 
HIF-1α isoform is the best characterized and seems to be the most important in the 
cellular response to hypoxia (99). The HIF-2α subunit, also known as endothelial PAS 
domain protein 1 (EPAS 1) or HIF-related factor (HRF), shares 48% sequence identity 
with HIF-1α, is inducible by hypoxia and binds to the HREs of hypoxia inducible genes 
(49, 58, 201, 220). Although HIF-1α and HIF-2α share significant structural and 
functional similarities, they appear to be inducible by different stimuli (22) and have 
different patterns of tissue distribution (219). The third variant HIF-3α, also known as 
inhibitory PAS domain protein (IPAS), undergoes an alternative splicing event which 
removes the transactivation domain, and by binding to HIF-1α rather than HIF-1β 
functions in a dominant negative manner (143, 144).  
It has been estimated that HIF-1 is capable of directly regulating approximately 
60 genes (180). These genes can be categorized into several groups based on their 
physiological roles, including angiogenesis, growth and apoptosis, ECM metabolism, 
oxygen transport and iron metabolism, and energy metabolism (Table 1) (177). Although 
expression of some of these genes, such as VEGF, are under the control of HIF-1 in a 
wide variety of cell types, many are regulated in a cell-type specific manner (180). As  
  
 
 
 
 
 
 
FIGURE 1. Overview of HIF-1α regulation. Under normal oxygen conditions 
(normoxia), HIF-1α levels are very low. This is due to the activity of tumor suppressors 
such as VHL and p53, which facilitate HIF-1α ubiquitination and degradation by the 
proteosome. When oxygen levels are low (hypoxia), interaction with the tumor 
suppressors is disrupted and HIF-1α rapidly accumulates. In addition to its stabilization 
by hypoxia, HIF-1α levels can increase due to activation of the PI3K-AKT-FRAP growth 
signaling pathway. HIF-1α accumulation by growth signaling results from an increased 
rate of synthesis.  
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TABLE 1. Examples of HIF-1 target genes. 
 
 
 Gene Function Reference 
VEGF Vascular endothelial 
cell growth  
(62) 
FLT-1 (VEGFR-1) VEGF receptor (68) 
FGFs Vascular endothelial 
cell growth  
(129) 
Angiogenesis 
 
PDGF Vascular endothelial 
cell growth  
 
(71, 129) 
Nip3 Growth and 
apoptosis 
Apoptosis (21)  
Insulin-like growth 
factor binding 
protein 1 (IGFBP-1) 
 
Binds and sequesters 
IGF 
(196)  
(UPAR) urokinase 
plasminogen 
activator receptor  
Degradation of ECM (78)  
Matrix 
metalloproteinase-2 
(MMP-2) 
Degradation of ECM (128) 
ECM metabolism 
Collagen prolyl-4-
hydroxylase 
 
Collagen synthesis (194)  
Glucose transporter-
1 
Glucose transport (46)  
6-phosphofructo-1-
kinase 
Glucose metabolism (181) 
Energy metabolism 
Phosphoglycerate 
kinase 1  
 
Glucose metabolism (57)  
TrOxygen transport 
and iron metabolism 
ansferrin Iron transport protein (172)  
Transferrin receptor Mediates cellular iron 
uptake 
(141, 192)  
Erythropoietin Haemoglobin synthesis (182) 
 
Genes in bold have confirmed HIF-1 binding sites, others are inducible by hypoxia and 
are suspected to have HIF-1 binding sites.  
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many of these genes are important for growth and survival, they are oncogenic and their 
disregulation can lead to tumor development and progression. Because of this, HIF-1α is 
often overexpressed in a wide variety of cancer types (180). 
Because HIF-1 is important for the regulation of so many genes, many of which 
are oncogenic proteins, expression and activity of the HIF-1α subunit is tightly 
controlled. Although there are some reports of regulation of HIF-1α mRNA (109, 200, 
210), the most frequently documented modes of HIF-1 regulation concerns abundance of 
the alpha subunit and HIF-1 transcriptional activation. Regulation of HIF-1α levels, as 
with all proteins, is determined by the rate of it’s synthesis versus the rate of its 
degradation. It is well documented that the rate of synthesis is determined by the activity 
of growth signaling pathways, and the rate of degradation by the availability of oxygen. 
Transcriptional activation of HIF-1 is controlled by both growth signaling pathways and 
oxygen availability. These modes of regulation will be discussed in greater detail in 
subsequent sections.  
Regulation of HIF-1α levels and activity occur primarily as a result of 
postranslational modification, and these modifications include hydroxylation, acetylation, 
and phosphorylation. Hydroxylation of multiple residues facilitates the response of HIF-
1α to hypoxia, and affects both the rate of degradation and the level of transcriptional 
activation. This will be discussed in greater detail in the following section. It is known 
that HIF-1α is subject to acetylation by the ARD1 acetyltransferase, and this reportedly 
facilitates its degradation by increasing interaction with VHL (108). Several residues of 
HIF-1α are phosphorylated (152, 169), as treatment with a phosphatase causes the 
multiple bands associated with HIF-1α western blot return to the predicted size of 104 
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kDa (152). The function of HIF phosphorylation is not entirely clear (11), but appears to 
be facilitated by MAPK and probably results in transcriptional activation by encouraging 
interaction with CBP/p300. 
 
Regulation of HIF-1 by hypoxia 
 
The most notable aspect of HIF biology is induction of the alpha subunit during 
hypoxia. Under normal oxygen conditions and without stimulation by growth/oncogenic 
signals, HIF-1α levels in vitro are very low and usually undetectable. This is due to its 
continual and rapid destruction via proteosomal degradation in the presence of OB2B. 
Degradation of HIF-1α during normoxia is extremely rapid, and the half-life has been 
estimated to be less than 5 minutes (98, 210). As the level of O B2B decreases, proteosomal 
degradation ceases and HIF-1α protein accumulates. In this manner, HIF-1 is capable of 
responding rapidly to changes in OB2B concentrations without having to wait for the 
lengthier processes of transcription and translation.  
The destruction of HIF-1α in the presence of OB2B is facilitated by tumor 
suppressors such as VHL. Loss of VHL, as occurs in von Hippel-Lindau (VHL) disease, 
results in normoxic expression of HIF-1α and re-introduction of wildtype VHL 
eliminates HIF-1α expression (147). It was determined that VHL physically interacted 
with HIF-1α in a region known as the oxygen-dependent degradation domain (ODD), 
mediating its ubiquitination and proteosomal degradation (figure 2) (195). Although it 
was known that interaction of HIF-1α and VHL only occurred in the presence of OB2B, and 
this interaction was abolished during hypoxia or treatment with iron chelators such as  
  
 
 
 
 
FIGURE 2. Structure of HIF-1α and regulation by prolyl hydroxylation. The basic 
helix-loop-helix (bHLH) domain and Per-Arnt-Sim (PAS) domain are required for 
dimerization and DNA binding. There are two transactivation domains, an amino-
terminal transactivation domain (TAD-N, or NAD) and a carboxyl-terminal 
transactivation domain (TAD-C, or CAD). An asparagine residue in the CAD is subjected 
to hydroxylation by the factor inhibiting HIF (FIH), resulting in increased transcriptional 
activity during hypoxia. Stability of the alpha subunit is mediated by the oxygen 
dependent degradation (ODD) domain. Two prolyl residues within the ODD are 
subjected to hydroxylation by the prolyl hydroxylase (PHD) enzymes during normoxia, 
which facilitate interaction with the E3 ubiquitin ligase VHL and result in HIF-1α 
destruction.  
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CoClB2B, it was not known how the actual level of oxygen was sensed. The mechanism of 
oxygen sensing became apparent with the discovery that VHL was only able to interact 
with HIF-1α when several critical conserved proline residues within the ODD were in a 
hydroxylated state (105, 106, 229). The enzymes responsible for hydroxylation of proline 
residues 402 and 564 were found to belong to a group of prolyl hydroxylase domain 
containing (PHD) enzymes. It was subsequently determined that there were three non-
heme containing iron dependent PHD enzymes that share significant homology and 
facilitate HIF-1α hydroxylation (145). During normoxia, the proline residues in the ODD 
domain are fully hydroxylated, facilitating interaction with the E3 ubiquitin ligase VHL 
and destruction of HIF-1α. As O B2B levels decrease, proline hydroxylation also decreases 
and the ability of VHL to interact with HIF-1α is diminished. In this manner, PHD 
enzymes control the rate of HIF-1α degradation in response to variations in oxygen 
availability. 
In addition to stabilization during hypoxia, it was known that HIF-1 
transcriptional activity was also elevated during hypoxia (111, 164). It was eventually 
determined that this was dependent on the hydroxylation state of asparagine residue 803 
in the transactivation domain (TAD) of HIF-1α. The enzyme responsible for its 
hydroxylation during hypoxia was determined to be an asparaginyl hydroxylase, also 
known as factor inhibiting HIF-1 (FIH-1) (132). During normoxia, the asparagine residue 
803 is hydroxylated disrupting interactions between HIF-1α and the transcriptional 
coactivator CBP/p300 (10, 48, 90, 131, 132). During hypoxia, asparaginyl hydroxylation 
is diminished, and interaction with CBP/p300 is increased. In this manner, both the 
amount of HIF-1α protein and its transcriptional activity is elevated during hypoxia. 
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Regulation of HIF-1 by growth signaling 
 
In addition to regulation by changes in oxygen levels, HIF-1α is regulated by 
receptor and non-receptor tyrosine kinases activity. Examples of growth signals, 
hormones, and cytokines capable of inducing HIF-1α are numerous, and include insulin 
(191, 204, 234), insulin-like growth factor-1 (IGF-1) (234), insulin-like growth factor-2 
(IGF-2) (51), PDGF (170), EGF (236), HGF (193), TNFα (89), IL-1β (89, 191, 200), 
angiotensin-2 (170) and thrombin (74, 170) (Table 2). Not only is HIF-1α induced by 
ligand stimulation of membrane bound receptors, multiple studies have shown that 
oncogene (TKs and RTKs) overexpression (or overactivtity) can also elevate HIF-1α 
levels. Examples of these include HER2P
NEU 
P(133), Ras (28, 148), v-Src (109). 
In contrast to stabilization of HIF-1α as occurs during hypoxia, its induction by growth 
signals has been shown to function by increasing the rate of its synthesis. This was 
demonstrated through the use of the translation inhibitor cyclohexamide and pulse 
labeling experiments (64, 133, 204). The majority of these studies implicated members of 
the kinase cascade involving the tyrosine kinase PI3-kinase (PI3K) and the serine-
threonine kinases AKT (protein kinase B) and FRAP (FKBP/rapamycin-associated 
protein, also known as mTOR, mammalian target of rapamycin), as critical for this 
enhanced rate of translation. The importance of these kinases was demonstrated 
repeatedly through the use chemical inhibitors (64, 191, 204, 236) and dominant negative 
versions (236). In addition, loss of the tumor suppressor phosphatase and tensin  
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TABLE 2. Regulators of HIF-1α expression or function.  
 
 Pathway Effects on HIF-1α Reference 
Ligands of tyrosine 
kinase receptors 
EGF Increased translation (236) 
 IGF-1 
 
Increased translation (234) 
 IGF-2 Increased translation (51) 
  
Insulin 
 
Increased translation 
 
(191, 204, 234) 
  
Heregulin 
 
Increased translation 
 
(133) 
  
PDGF 
 
Increased translation 
 
(170) 
 
 
Ligands of other 
receptors 
 
Thrombin 
 
Increased translation  
 
(74, 170) 
 Angiotensin Increased translation 
 
(170) 
Oncogenes 
 
MAPK Increased transactivation (169) 
 RAS  Increased translation (28) 
  
v-Src 
 
Increased translation,  
increased transcription 
 
(109) 
  
c-Src 
 
Increased translation 
 
(116) 
  
PI3K/AKT 
 
Increased translation 
 
 
(64, 191, 204, 
236) 
 
Tumor suppressors PTEN Decreased translation (238) 
  
VHL 
 
Increased degradation 
 
(147) 
  
P53 
 
 
Increased degradation 
 
(167) 
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homologue deleted on chromosome 10 (PTEN), a negative regulator of AKT, or 
expression of constitutively active AKT also increased levels of HIF-1α (236, 238). 
Furthermore, induction of HIF-1α by non-receptor tyrosine kinases such as c-Src (pp60c- 
src) (116), v-Src (109), and Ras (28, 148) function via increased translation which is 
dependent on the PI3K/AKT/FRAP pathway.  
The ability of the PI3K/AKT/FRAP kinase cascade to increase the rate of HIF-1α 
synthesis probably depends on the ability of FRAP to phosphorylate two important 
components of the translational machinery; eIF-4E binding protein 1 (4E-BP1) and p70 
S6 kinase (S6K) (11) (Figure 3). Following phosphorylation, 4E-BP1 loses the ability to 
inhibit eukaryotic translation initiation factor 4E (eIF-4E), resulting in increased 
recruitment of 40S ribosomal subunit to the 5’ cap structure of the mRNA (11). In 
addition, phosphorylated FRAP activates S6K which enables activation of the 40S 
ribosomal protein S6, resulting in increased transcription of mRNAs with a 5’ 
polypyrimidine tract (70, 208). The ability of the PI3K/AKT/FRAP kinase cascade to 
increase the rate of HIF-1α synthesis is dependent on the presence of the 5’-UTR of the 
HIF-1α mRNA, as removal of this sequence abolished the effects of heregulin (133). 
In addition to HIF-1α regulation by the PI3K/Akt pathway, it has been reported that 
MAPK signaling is instrumental in receptor mediated activation of HIF-1 (64). Although 
its role in regulation of HIF-1α is not as well studied as PI3K/AKT, activation of p42/p44 
MAPK seems to result in transcriptional activation of HIF-1 (152, 169, 188). Direct 
phosphorylation of HIF-1α by MAPK has been reported (152, 169), and the probable 
result of HIF-1α phosphorylation is increased transcriptional activation by  
  
 
 
 
 
 
FIGURE 3. Mechanism of HIF-1α regulation by growth signaling Activation of PI3K 
results in a kinase cascade involving AKT and mTOR. Activated mTOR phosphorylates 
p70 S6 kinase (S6K) which in turn phosphorylates S6, increasing transcription of 
mRNAs with a 5’ polypyrimidine tract. Furthermore, activated mTOR phosphorylates 
eIF-4E binding protein 1 (4E-BP1), which consequently loses its ability to inhibit 
eukaryotic translation initiation factor 4E (eIF-4E). Unrepressed eIF-4E facilitates 
recruitment of 40S ribosomal subunit to the 5’ cap structure of the mRNA.  
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disrupting interactions with FIH, the transcriptional suppressor of HIF-1α (11). 
Furthermore, several groups have reported MAPK activation by hypoxia in several cell 
lines (34, 148, 152), so it is possible that MAPK activity enhances both signal mediated 
and hypoxic transcriptional activation of HIF. 
 
Signal transducer and activator of transcription 
 
 Signal transducers and activators of transcription (STATs) are a group of 
transcription factors that in the unphosphorylated form exist in a latent state in the 
cytoplasm (138). STATs undergo tyrosine phosphorylation by a variety of tyrosine 
kinases, including both receptor tyrosine kinases (RTKs) and non-receptor TKs (figure 
4). Many membrane bound receptors do not have intrinsic tyrosine-kinase activity, and 
therefore require the assistance of the Janus Kinase (JAKs) (23). Furthermore, STAT 
phosphorylation can result from the activity of non-receptor tyrosine kinases such as Src 
and Abl (37, 228). Phosphorylation of a single tyrosine residue near the carboxy terminus 
results in homo- or hetero-dimerization via interaction with the Src-homology-2 (SH2) 
domain of the other STAT protein (186). Furthermore, several STAT proteins undergo 
serine phosphorylation in the carboxy-terminal transactivation domain resulting in 
increased transcriptional activity (217). Following tyrosine phosphorylation and 
translocation to the nucleus, Stats bind to promoters containing the consensus sequences 
TT(N B4B)AA and  TT(N B5B)AA (179). Stats control a variety of genes, particularly those 
involved with cell growth, survival, and immune function (230).  
 
  
 
 
 
 
 
 
FIGURE 4. Stat3 signaling pathway. Binding of growth factors or cytokines to their 
receptors results in activation of intrinsic receptor tyrosine kinase activity or recruitment 
and activation of receptor associated kinases such as janus kinase (JAK). The 
cytoplasmic tail of the receptor undergoes phosphorylation providing a docking site for 
non-phosphorylated latent Stat monomers. Recruited Stats undergo tyrosine 
phosphorylation, followed by dimerization and translocation to the nucleus. 
Phosphorylated Stat homo- or hetero-dimers bind to and activate promoters of genes 
involved with survival, growth, immunity and angiogenesis. 
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There are seven isoforms of Stat proteins, Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b, 
and Stat6. Of these different isoforms, Stat1, Stat3, and Stat5 are commonly activated in a 
variety of cancers (23). However, because Stat1 is primarily growth suppressive, it is  
not likely that it contributes to oncogenesis (19). There is a wealth of evidence to indicate 
that Stat3 and Stat5 are important for tumor progression. Stat5 is commonly activated in 
and appears to be important for various leukemias (23). On the other hand, Stat3 is 
activated in a wide variety of cancer types, including leukemia (76), multiple myeloma 
(25), breast cancer (66, 213), head and neck cancer (80), prostate cancer (157) and 
melanoma (158). 
There is an abundance of evidence defining a critical role for Stat3 in oncogenesis 
(15, 17). Transfection of cells with Stat3C, in which substitution of two residues with 
cysteine results in spontaneous dimerization and constitutive activity, results in 
transformation and tumor formation in nude mice (20). Furthermore, Stat3 is necessary 
for cellular transformation mediated by v-Src (18, 205). It is well established that Stat3 
signaling contributes to oncogenesis by preventing apoptosis (25, 79, 80) and blocking 
Stat3 signaling induces apoptosis in a variety of tumors (25, 80, 158). Inhibition of Stat3 
signaling prevents expression of Bcl-xBL,B an important anti-apoptotic protein (25, 80, 158). 
Furthermore, it has also been demonstrated that Stat3 controls cell cycle progression by 
regulating D1 (20). These reports and others firmly establish Stat3 as an important 
facilitator of oncogenesis. 
Although Stat3 itself is not mutated in tumors, it is activated by and required for 
the transforming capabilities of many oncogenic proteins. For example, Stat3 is activated 
in cells transformed with v-Src and v-Abl oncogenes (37, 228) and is required for the 
 23
transforming ability of v-Src (14, 18, 205). Furthermore, Stat3 is induced by a variety of 
cytokines and growth factors commonly over-expressed by cancer cells, including EGF, 
PDGF, and IL-6 (14, 25, 80, 157). These reports and others demonstrate that Stat3 is an 
important facilitator for many oncogenic proteins.  
 
Stat3 and angiogenesis 
 
There is accumulating evidence that Stat3 is an important facilitator of tumor 
angiogenesis. Stat3 activation correlates with VEGF production in a variety of human 
cancers, including breast, head and neck, melanoma, and pancreatic cancer cell lines  
(159, 214) as well as VEGF mRNA in pancreatic cancer specimens from patients (214). 
Furthermore, many of the growth/oncogenic signaling pathways capable of increasing 
VEGF production also result in activation of Stat3. For example it has been reported that 
activation of both EGFR and Src signaling pathways result in increased production of 
VEGF (47, 155, 161, 218), and it is well documented that stimulation of these pathways 
results in Stat3 activation (18, 66, 67, 79, 205, 228). These data indicate that there is a 
strong correlation between Stat3 activation and VEGF expression in a variety of cancers. 
Several publications have shown that Stat3 is required for VEGF expression in 
various cancer cell lines. Blocking constitutive Stat3 activity in tumor cells with a 
dominant negative version downregulates basal levels of VEGF expression  (159, 214). 
Furthermore, it has been shown that Stat3 is necessary for VEGF induction resulting from 
both growth signals and tyrosine kinases. In cells transformed with v-Src there is high 
expression of VEGF and Stat3 activity, and blocking Stat3 significantly reduces VEGF 
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levels (159). Induction of VEGF in by IL-6 or glycoprotein (gp) 130 (a subunit of the IL-
6 receptor) is dependent on Stat3 signaling (65, 215). Furthermore, Stat3 is required for 
VEGF induction by oncostatin-M (OSM) in an astroglioma cell line (168).  
Transfection with Stat3C results in constitutive Stat3 activation and induces 
VEGF expression in both normal fibroblasts and B16 tumor cells (159). Furthermore, 
B16 cells transfected with Stat3C demonstrated increased angiogenesis when placed in 
matrigel and inserted into C57BL/6 mice (159). A putative Stat3-responsive element 
(SRE) sequence spanning –842 to –849 successfully competed with hSIE probe (159) and 
itself was able to function as a probe in EMSA (214). Furthermore, VEGF promoter 
activation by v-Src and constitutively activated Stat3 was abrogated when this same 
sequence was mutated (159, 214). Stat3 binding to the VEGF promoter in vivo was 
confirmed by chromatin immunoprecipitation assays in v-Src transformed NIH3T3 cells 
(159). These reports establish that Stat3 increases VEGF production by directly binding 
to and activating its promoter. 
In addition to its effects on VEGF, Stat3 has been implicated as a facilitator of 
angiogenesis by other mechanisms. It has recently been demonstrated that Stat3 regulates 
expression of both MMP-2 and MMP-9, important facilitators of both angiogenesis and 
metastasis (41, 149, 223). It has also been reported that Stat3 is necessary for signaling by 
receptors associated with angiogenic ligands, including bFGFR and VEGFR (7, 42, 176). 
Furthermore, it has been demonstrated that Stat3 is necessary for the mitogenic effects of 
the angiogenic factor PDGF (14). It has also been reported that Stat3 is required for 
endothelial cell migration and microvascular tube formation (225). These data implicate 
Stat3 as a key facilitator of angiogenesis beyond regulation of VEGF.  
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It has recently been reported that there is a combined requirement for both Stat3 
and HIF-1 for maximum VEGF induction by hypoxia or Src (82). Through the use of 
CHIP assays, the authors show that HIF-1 and Stat3 bind simultaneously to the VEGF 
promoter in response to activated Src or the hypoxia mimic CoCl B2B. They also demonstrate 
that both Stat3 and HIF-1 are required for maximum activity of a luciferase reporter 
construct under the control of the VEGF promoter. When either HIF-1 or Stat3 was 
blocked with a dominant negative version, there was an equivalent loss of reporter 
activity. Furthermore, they show that both HIF-1α and Stat3 coimmunoprecipitate with 
each other as well as the transcriptional activator p300. It is not entirely surprising that 
they could form a complex on the VEGF promoter, as the HIF-1 binding site spans –985 
to –935, and the Stat3 binding site is 86 bp downstream at –849 to –842 (62, 159). 
Although the authors demonstrate that both HIF-1α and Stat3 are required for VEGF 
expression, they do not show the effects of blocking Stat3 activity on HIF-1α expression. 
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OBJECTIVES 
 
The overall objective of the studies conducted in this dissertation was to 
investigate the role of Stat3 in regulating tumor angiogenesis, in particular expression of 
HIF-1α and VEGF. It had recently been determined that Stat3 is a transcriptional 
activator of VEGF, and is essential for angiogenesis (159, 214). However, the role of 
Stat3 in regulating HIF-1α, the other main transcriptional regulator of VEGF, had not 
been examined. Results from preliminary experiments suggested that blocking Stat3 
prevented both basal level expression and the hypoxic induction of HIF-1α. These 
findings lead to the hypothesis that Stat3 is required for HIF-1α expression, and blocking 
Stat3 signaling could abrogate both tyrosine kinase and hypoxia induced HIF-1 activity 
and VEGF expression. In order to verify this hypothesis, the following aims were 
pursued. 
 
Aim I. To determine the role of Stat3 in HIF-1α expression induced by growth 
signals.  
 
(A) To determine the mechanism by which IL-6 induces HIF-1α expression. It had 
been reported that stimulation of a variety of receptor tyrosine kinases results in increased 
HIF-1α levels during normoxia (64, 133, 204, 236). However, it had not been determined 
if stimulation with IL-6 resulted in elevated levels of HIF-1α. Because Stat3 is an 
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important facilitator of IL-6 signaling, the role of Stat3 in IL-6 induced HIF-1α 
expression was examined. 
 
(B) To determine if Stat3 is required for HIF-1α induction by oncogenic growth 
signals other than IL-6. Multiple growth signals that activate Stat3 also result in 
elevated expression of HIF-1α during normoxia. For example, stimulation with 
epidermal growth factor (EGF) increases both Stat3 activation and HIF-1α expression 
(236, 237). Because it had been observed that Stat3 was required for HIF-1α induction by 
IL-6, experiments were performed to determine if Stat3 was also required for increased 
HIF-1α expression resulting from heregulin and EGF. 
 
Aim II. To determine the role of Stat3 in the cellular response to hypoxia. 
 
(A) To determine if Stat3 is required for the hypoxic induction of HIF-1α and 
hypoxia inducible genes. It has been reported that inhibiting the AKT/PI3K pathway 
does not limit the induction of HIF-1α by hypoxia (2, 6). This suggests that expression of 
HIF-1α due to growth signaling and hypoxia result from separate and independent 
mechanisms. Because it had been observed that blocking Stat3 signaling prevented both 
basal HIF-1α expression and its induction by growth signals, experiments were 
performed to determine if the hypoxic induction of HIF-1α was also prevented. 
Furthermore, the role of Stat3 in the hypoxic induction of VEGF and MMP-2 was 
examined.   
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(B) To characterize Stat3 activation by hypoxia. HIF-1 is an important regulator of the 
VEGF gene in response to hypoxia. Because it has been reported that Stat3 is also a 
transcriptional regulator of VEGF, and preliminary experiments in the laboratory 
suggested that Stat3 was necessary for HIF-1α induction by hypoxia, Stat3 activation by 
hypoxia was examined. Furthermore, the time-course of Stat3 activation in relation to 
HIF-1α and VEGF induction was studied. 
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MATERIALS AND METHODS 
 
Reagents and antibodies 
 
The following reagents and antibodies were purchased from various companies as 
indicated: Interleukin 6 (BD Pharmingen); heregulin (Sigma); EGF (Sigma); 
Cyclohexamide (Calbiochem); G418 (Cellgro); CoClB2B (sigma); Anti-VEGF monoclonal 
antibody (R&D); Anti-HIF-1α polyclonal antibody and Anti-β-actin monoclonal 
antibody (Santa Cruz Biotechnology); Anti-HIF-1β monoclonal antibody (NOVUS 
Biologicals); Anti-Phospho-Akt (Cell Signaling). Anti-Akt1 monoclonal antibody was a 
kind gift from Dr. J. Cheng (University of South Florida College of Medicine, Tampa).  
 
Cell lines and cell culture 
 
BALB/c-3T3 fibroblasts and v-Src-transformed BALB/c 3T3 fibroblasts were grown in 
Dulbecco’s modification of Eagle’s medium (DMEM) with 10% calf serum (CS) and 1% 
antibiotic-antimycotic (Gibco). MCF-7, DU-145, and A2058 tumor cells were grown in 
RPMI 1640 with 10% FBS and 1% antibiotic-antimycotic. BALB/c fibroblasts were a 
gift from Dr. Jack Pledger (H. Lee Moffitt Cancer Center, Tampa, Florida). BALB/c 
fibroblasts transformed with v-Src were a gift from Dr. Richard Jove (H. Lee Moffitt 
Cancer Center, Tampa, Florida). A2058 human melanoma, DU145 human prostate 
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cancer and MCF-7 human breast cancer cells were obtained from ATCC (Rockville, 
MD).  For culture under hypoxia, cells were placed in a modular incubator chamber 
(Billups-Rothenberg). The chamber was sealed and flushed with a gas mixture containing 
1% O B2B, 5% CO B2B, and 94% N B2 Bfor 10-15 minutes, and then incubated at 37°C. 
 
Treatment With Src Tyrosine Kinase Inhibitors 
 
PD166285 (127) and PD180970 (127) were dissolved in 100% dimethyl sulphoxide 
(DMSO) and stored at -80 P
o
PC. The stocks were diluted into the media, immediately prior 
to use. 
 
Generation of cell lines stably transfected with Stat3 siRNA 
 
The Stat3 siRNA oligonucleotide, AATTAAAAAAGTCAGGTTGCTGGTCAAATTCT 
CTTGAAATTTGACCAGCAACCTGACTTCC, was inserted into pSilencer 1.0-U6 
siRNA expression vector (Ambion).  To generate siRNA/Stat3 stable tumor cell clones, 
the pSilencer 1.0-U6 Stat3 siRNA expression vector (1ug) was co-transfected with 
pcDNA3 (0.1µg) into MCF-7 and A2058 cells using Lipofectamine (Invitrogen) as 
described below, followed by selection with hygromycin  (300 µg/ml). MCF-7 and 
A2058 clones stably transfected with the empty pSilencer/pcDNA3 were used as a 
control.   
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Retrovirus infection 
 
The stable retrovirus-producing cell lines HEK 293T expressing Stat3D and MSCV (the 
control retrovirus vector) were generous gifts from Dr. D. Link (Washington University, 
Seattle). For retrovirus infection, supernatant was collected from confluent retrovirus-
producing cells following a 48 hour incubation. The supernatant was supplemented with 
8 µg/ml polybrene. BALB/c-3T3 v-Src cells were seeded at 1.5 X 10 P
6 
Pin a 10cm plate the 
day prior to infection. The following day, cells were cultured in viral supernatant for 4-8 
hours, then the viral supernatant was replaced with normal growth media. This was 
repeated up to three times until 100% infection efficiency had been achieved, as 
visualized by fluorescent microscopy.  
 
Anti-sense oligonucleotide and Stat3 siRNA transient transfections 
 
For transfection with antisense oligonucleotide, human tumor cells were seeded in 6-well 
plates at 2.5 x 10P
5
P or 10cm dishes at 1.5 x 10 P
6
P for 18-24h prior to transfection. Cells were 
transfected with either 1 µg of plasmid DNA or 300 nM oligonucleotide using 
Lipofectamine and Lipofectamine plus reagents (Life Technologies), according to the 
manufacturer’s protocol.  The sequence for Stat3 antisense oligonucleotide was 5’-
GCTCCAGCATCTGCTGCTTC-3’.  The sequence for control oligonucleotide was 5’–
GCTCCAATACCCCGTTGCTTC-3’.  For transient transfection with Stat3 or HIF-1α 
(Dharmacon), cells were seeded at 2.5 x 10 P
5 
Pper well of 6-well plates 18-24h prior to 
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transfection. Cells were transfected with 10-50nM siRNA using transit TKO transfection 
reagent (Mirus), according to the manufacturer’s protocol.    
 
Preparation of whole cell and nuclear extracts 
 
For preparation of whole cell extracts, cells were washed 3x with ice cold phosphate-
buffered saline (PBS), scraped into PBS and pelleted by centrifugation at 2500 x g for 5 
min at 4C. Pellets were resuspended in RIPA triple detergent lysis buffer (50 mM Tris 
(pH 7.4), 5 mM EDTA, 150 mM NaCl, and 0.5% Triton-X-100, 1 mM PMSF, 2 µg/ml 
leupeptin, 2 µg/ml aprotinin, and 2 µg/ml pepstatin), then incubated on ice for 30 min. 
Lysates were centrifuged at 15000 x g for 30 min. Supernatants were collected and 
protein concentration was determined using the Bradford assay. For preparation of 
nuclear extracts, cells were washed 3x with ice cold PBS (supplemented with 100 mM 
Na B3BVO B4B, 100 mM NaF), scraped into PBS and pelleted by centrifugation at 2500 x g for 5 
min at 4°C. Pellets were resuspended in hypotonic buffer A (10mM Tris-HCl (pH 7.6), 
1.5 mM MgClB2, B10 mM KCl, 2mM DTT, 0.4 mM PMSF, 1mM Na B3BVO B4B, 2 µg/ml 
leupeptin, 2 µg/ml aprotinin, and 2 µg/ml pepstatin) then centrifuged at 2500 x g. Cells 
were resuspended in buffer A + 1% NP-40 then incubated on ice for 10 min. Cells were 
centrifuged for 10 min at 10,000 x g. The supernatant (cytoplasmic extract) was 
discarded, and the pellet was resuspended in hypertonic buffer C (0.42 M KCl, 20 mM 
Tris-HCl (pH 7.6), 20% glycerol, 1.5 mM MgCl B2B, 2mM DTT, 0.4 mM PMSF, 1 mM 
Na3VO4, 2 µg/ml leupeptin, 2 µg/ml aprotinin, and 2 µg/ml pepstatin). Following 
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stirring for 30 min at 4°C, extracts were spun at 15,000 x g for 30 min. Supernatants were 
collected (nuclear extract) and concentration was determined using the Bradford assay. 
 
Western Blotting 
 
Equal amounts of whole cell or nuclear extract (30-50 µg of NE or 100 µg of WCE) were 
dissolved in Laemmli SDS-PAGE sample buffer (100mM Tris-HCl (pH 6.8), 4% SDS, 
0.2% Bromophenol, 20% glycerol, 2% 2-mercaptoethanol, 1mM DTT) and boiled at 
100°C for 5 min prior to separation by SDS-polyacrylamide gel electrophoresis. Samples 
were applied to 8% polyacrylamide gels for nuclear extracts and 12% polyacrylamide 
gels for whole cell extracts. Electrophoresis was generally performed at 50 V for 
approximately 16 hours. For transfer, the Gel, PVDF membrane (Millipore), and filter 
papers were soaked in transfer buffer (25 mM Tris base, 192 mM glycine, 20 % 
Methanol) for approximately 5 min.  The gel and membrane were sandwiched between 
the filter papers and placed in a semidry electroblotter (Owl Separation Systems). 
Transfer was generally performed at 200 mAmps for 4 hours (current varied depending 
on gel size, but never exceeded Area (cm) X 3 mAmps). Following transfer, even loading 
and transfer was confirmed by staining the membrane with Ponceau S solution (Sigma). 
The membrane was blocked by incubation for 1 hour at room temperature in blocking 
buffer (PBS containing 5% non-fat dry milk and 0.1% Tween). Membranes were probed 
with primary antibody dissolved in blocking buffer at the following concentrations: HIF-
1α rabbit polyclonal (H-206) (1:500 dilution), HIF-1β mouse monoclonal (1:1,500 
dilution), B-actin mouse monoclonal (1:5000), AKT1 mouse monoclonal (1:1,000 
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dilution), phospho-AKT rabbit polyclonal (1:1,000 dilution), and VEGF mouse 
monoclonal antibody (1:500 dilution). Probing with primary antibodies was performed 
for 3 hours at room temperature or overnight at 4°C. Membranes were washed with 
washing buffer (PBS with 0.1% Tween) twice for 5-10 min each. Membranes were 
probed with secondary antibody dissolved in blocking buffer at the following 
concentrations for one hour: Horseradish peroxidase-conjugated sheep anti-mouse 
(1:2,500) and donkey anti-rabbit (1:5,000). Following incubation with secondary 
antibody, membranes were washed with washing buffer for 15 min three times.  The 
signal was developed with SuperSignal West Pico Chemiluminescent Substrate 
(PIERCE) according to manufacturer’s instructions. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
 
Binding reactions were carried out in a total volume of 20ul containing 4-8 µg of 
normalized nuclear extract in (10 mM HEPES, 10% glycerol, 1 mM DTT, 0.1µg/µl poly 
(dI:dC), 0.5  g/ul BSA, 80mM NaCl). The P
32
P -radiolabeled hSIE (Stat3 and Stat1 specific 
high affinity Sis-Inducible Element, 5’-AGCTTCATTTCCCGTAAATCCCTA) probe 
was added and samples were incubated for 30 min at 30°C. Following the binding 
reaction, protein-DNA complexes were resolved by 5% non-denaturing polyacrylamide 
gel electrophoresis (PAGE). Electrophoresis was carried out at 200 V in 0.25 X Tris-
borate-EDTA (TBE) (1x TBE is 89 mM Tris-HCl, 89 mM boric acid, and 5 mM EDTA) 
for 2-3 hours. Gels were fixed with fixing buffer (10% Methanol, 10% acetic acid), 
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vacuum dried at 80°C for 2 h, and autoradiographed with intensifying screens at –80°C 
for 1 to 5 days 
 
RNA isolation and Northern blotting 
 
Total RNA was isolated (from 1.5 x 10 P
6
P cells seeded in 10-cm dishes) using TRIzol 
reagent (Invitrogen) according to the manufacturer’s instructions. 15-µg aliquots were 
added to 15ul loading buffer (Sigma) and samples were denatured at 65°C for 15 min. 
Samples were loaded into a 1% agarose-formaldehyde gel (containing ethidium bromide) 
and electrophoresed at 80 volts for approximately 5 hours in 1X MOPS (10X Mops is 0.4 
M Morpholinopropanesulfonic acid, 0.1 M Sodium acetate–3 HB2BO, 10 mM EDTA-Na B2B-2 
H B2BO, pH 7.2) solution. Prior to transfer, the gel was photographed under UV light to 
verify equal loading by visualization of the 18S and 28S rRNA bands. The gel, nylon 
membrane (PerkinElmer), and whatman filter paper were presoaked in 10X SSC prior to 
transfer. RNA was transferred to membrane in 10x standard saline citrate (SSC) by 
upward capillary transfer. The membrane was washed briefly in 2X SSC and ultra-violet 
cross-crosslinked using a UV-Stratalinker 2400 (Stratagene, La Jolla, CA, USA).  
For preparation of the HIF-1α probe, the entire HIF-1α cDNA (3.2 Kbp) was P
32
P -
radiolabeled using All-in-OneP
TM
P random primer DNA labeling mix (-dATP) (Sigma) 
according to the manufacturer’s protocol. The radiolabeled cDNA was purified using a 
G-25 sephadex column (Roche) according to the manufacturer’s protocol. To detect the 
HIF-1α transcript, the membrane was first pre-hybridized at 68°C for at least 5 min in 
hybridization buffer (Sigma). The radiolabelled cDNA was denatured by heating to 
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100°C for 10 min followed by placement on ice for 2 min. The denatured probe was 
added to the warm pre-hybridization solution, and the membrane was hybridized 
overnight at 42°C. The following day, the membrane was washed at least twice at 60°C 
with 2x SSC for 15 min, and then exposed to a phosphoimaging plate for 3 hours 
(Molecular Dynamics). 
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RESULTS 
 
Aim I: To determine the role of Stat3 in HIF-1α expression induced by growth 
signals. 
 
IL-6 increases levels of HIF-1α protein 
 
Multiple studies have shown that HIF-1α expression is increased by a variety of 
growth/oncogenic signals. Examples of these signals include heregulin (133), EGF (236), 
IGF-1 (234), TNFα (89), IL-1β (89, 191, 200) and others. In addition to HIF-1α, many of 
these signals also increase expression of VEGF (32, 63, 139, 174). Although it has been 
reported that stimulation with IL-6 results in increased production of VEGF (33, 38), it 
has not been demonstrated that it increases HIF-1α expression. 
Here we demonstrate that stimulation of MCF-7 human breast cancer with IL-6 
results in increased expression of HIF-1α protein in a dose dependent manner (Figure 5). 
MCF-7 cells were serum starved for 20 hours followed by stimulation with IL-6 in serum 
free media at the indicated concentrations for 6 hours. Nuclear extracts were collected 
and western blot analysis was performed. Nuclear extracts are used throughout this 
dissertation for the detection of HIF-1α by Western blot. Although HIF-1α can be 
detected using whole cell extracts, levels are low and the bands are often weak due to the 
extremely short half-life of HIF-1α under normoxia. Band intensity and broadness is 
significantly increased through the use of nuclear extracts. 
 
  
 
 
 
 
 
 
 
 
FIGURE 5. IL-6 increases HIF-1α protein in MCF-7 breast cancer cells. MCF-7 
cells (1.5 x 10 P
6
P) were cultured for 20h in serum free media followed by treatment with 
IL-6 in serum free media at the indicated concentrations for 6h. Nuclear extracts (30ug) 
were analyzed by western blotting using the indicated antibodies. HIF-1β and β-actin are 
used to verify equal loading. 
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The vast majority of reports concerning HIF-1α regulation by growth signals and 
cytokines indicate that increased expression of HIF-1α occurs without a concurrent 
increase in mRNA (11), however exceptions have been reported (200). To determine if 
this was true for IL-6, total RNA was collected from MCF-7 cells following treatment 
with IL-6 for 6h and analyzed by Northern blotting (Figure 6). Results demonstrate that 
the increase in HIF-1α levels resulting from IL-6 stimulation of MCF-7 cells cannot be 
accounted for by changes in levels of mRNA.  
 
IL-6 increases HIF-1α expression by increasing its rate of synthesis 
 
A majority of studies show that increased expression of HIF-1α resulting from 
stimulation with growth/oncogenic signals is due to an increase in the rate of its 
synthesis. Examples include heregulin (133), insulin (204), and IGF-1 (64), in which the 
authors directly show that elevated levels of HIF-1α were the result of an increased rate 
of synthesis. This was demonstrated through the use of the translation inhibitor 
cyclohexamide (CHX) and/or pulse labeling experiments. In contrast, increased HIF-1α 
expression resulting from hypoxia is due to protein stabilization, or cessation of the 
continuous degradation that occurs during normoxia. 
To determine if IL-6 stimulation results in an increased rate of HIF-1α synthesis 
or in a decreased rate of degradation, cyclohexamide was utilized. If IL-6 stimulation 
stabilizes HIF-1α protein, the addition of cyclohexamide to halt protein synthesis  
 
  
 
 
 
 
 
FIGURE 6. IL-6 does not increase HIF-1α mRNA in MCF-7 breast cancer cells. 
MCF-7 cells (1.5 x 10P
6
P) were cultured for 20h in serum free media followed by treatment 
with IL-6 in serum free media at the indicated concentrations for 6h. RNA (15ug) was 
analyzed by Northern blotting using a HIF-1α cDNA probe. A photograph of the 
ethidium bromide-stained gel indicates equal loading as demonstrated by the 18S and 28S 
rRNA bands. 
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following pre-treatment with IL-6 would not affect levels of HIF-1α. However, if IL-6 
increases the rate of HIF-1α synthesis, then the addition of CHX would counteract this 
and a rapid loss of HIF-1α protein would occur. To determine which of these was 
occurring, MCF-7 cells were treated with IL-6 for 6h followed by extraction of nuclear 
proteins and Western blot analysis (Figure 7). HIF-1α levels were significantly decreased 
as soon as 15 min following addition of CHX and returned to baseline within 1 hour, 
demonstrating that increased HIF-1α expression resulting from IL-6 stimulation is due to 
an increased rate of synthesis. 
 
Stat3 is required for IL-6 induction of HIF-1α 
 
Many of the growth/oncogenic signals that increase HIF-1α expression also result 
in activation of Stat3. It is well established that Stat3 is activated in response to 
stimulation with IL-6 (237). Furthermore, it has been reported that IL-6 results in 
increased production of VEGF (33, 38) and Stat3 is essential for this effect (215). We 
have shown here that IL-6 stimulation upregulates HIF-1α expression by increasing the 
rate of its synthesis. Because it was known that blocking Stat3 signaling prevented VEGF 
induction by IL-6 (215), as well as tumor angiogenesis (159, 214), we wanted to 
determine if HIF-1α expression resulting from IL-6 stimulation was also dependent on 
Stat3 signaling.  
MCF-7 cells were stably transfected with pSilencer expressing Stat3 siRNA, or 
with empty pSilencer. These cells were treated with IL-6 for 6 hours in duplicate and 
both whole cell and nuclear extracts were collected. Western blot analysis was performed  
  
 
 
 
 
 
 
 
 
 
 
FIGURE 7. IL-6 induced HIF-1α levels are due to synthesis and not cessation of 
degradation. MCF-7cells (1.5 x 10P
6
P) were cultured for 20h in serum free media followed 
by treatment with IL-6 (20 ng/ml) in serum free media for 6h. Cyclohexamide (100µM) 
was added for the indicated times. Nuclear extracts (30µg) were analyzed by western 
blotting using the indicated antibodies. HIF-1β and β-actin are used to verify equal 
loading. 
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to determine the levels of HIF-1α and VEGF. Results indicate that when Stat3 is silenced 
in MCF-7 cells, levels of HIF-1α are significantly lower compared to the control in both  
untreated and IL-6 treated cells (Figure 8). Furthermore, VEGF levels are dramatically 
reduced both at the basal level and following induction by IL-6 (Figure 8).  
 It is well documented that induction of HIF-1α by growth/oncogenic signals is 
due to increased synthesis. Furthermore, this increased rate of synthesis is the result of 
activation of growth signaling pathways, in particular the PI3K/AKT pathway (11). It is 
known that stimulation with IL-6 results in PI3K/AKT activation (88). Also, through 
correspondence with Dr. J. Cheng (University of South Florida College of Medicine, 
Tampa), we learned that Stat3 is a direct transcriptional activator of the AKT-1 gene. 
This suggested to us the potential mechanism that Stat3 may be regulating HIF-1α 
induction by controlling expression of AKT-1. 
To determine if Stat3 regulates Akt expression in MCF-7 cells, both total levels of 
Akt1 and phosphorylated levels of Akt1 and Akt2 were examined in cells stably 
transfected with Stat3 siRNA. Treatment with IL-6 resulted in increased levels of total 
Akt1 and phosphorylated Akt1 and Akt2 (figure 9). Following silencing of Stat3, basal 
levels of Akt1 as well as its induction by IL-6 was abolished. Furthermore, 
phosphorylated levels of both Akt1 and Akt2 were dramatically reduced. These results 
suggest a potential mechanism by which Stat3 regulates HIF-1α expression. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8. Silencing Stat3 blocks IL-6 induction of HIF-1α. MCF-7 cells were 
stably-transfected with empty pSilencer/pcDNA3 or pSilencer/pcDNA3 with Stat3 
siRNA. Cells were serum starved for 20h followed by treatment with or without IL-6 (20 
ng/ml). Nuclear extracts (30µg) (Top panel) and whole cell extracts (100µg)  (middle 
panel) were analyzed by Western blotting using the indicated antibodies. Stat3 DNA 
binding was determined by EMSA using nuclear extracts (8ug) (bottom panel). 
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FIGURE 9. Silencing Stat3 decreases AKT levels. MCF-7 cells (1.5 x 10 P
6
P), stably-
transfected with empty pSilencer or pSilencer-Stat3 siRNA, were cultured in serum free 
media for 20h followed by treatment with IL-6 for 6h. Whole cell extracts (100µg) were 
obtained and analyzed by Western blotting using the indicated antibodies. The antibody 
used for detecting phospho-Akt (pAkt) recognizes both Akt1 and Akt2.  For the total Akt 
protein detection, the antibody is specific for Akt1.   
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Stat3 is required for HIF-1α induction by Heregulin 
 
Many growth signals capable of activating Stat3 also increase expression of HIF-
1α. Examples of these include EGF (236, 237) and PDGF (64, 170, 207). Because we 
have observed that blocking Stat3 limits the ability of IL-6 to induce HIF-1α, we wanted  
to know if induction of HIF-1α by other growth signals was also prevented when Stat3 
was silenced.  
Comparable to published results (133), we observed a dose dependent induction 
of HIF-1α when MCF-7 cells were stimulated with heregulin for 6h (Figure 10). 
Furthermore, coordinate Stat3 activation was observed as determined by EMSA. To 
determine if Stat3 is required for HIF-1α induction by heregulin, MCF-7 cells expressing 
Stat3 siRNA were again utilized. Following stimulation with heregulin for 6h, HIF-1α 
was induced in control cells but not in Stat3 siRNA cells (Figure 11). Furthermore, 
VEGF expression was increased by stimulation with heregulin only in control cells. As 
previously seen in MCF-7 cells, basal level expression of both HIF-1α and VEGF was 
blocked. These data show that Stat3 is required for the induction of both HIF-1α and 
VEGF by heregulin in MCF-7 breast cancer cells. 
 
Stat3 is required for HIF-1α induction by EGF 
 
In addition to heregulin, it has been reported that stimulation with EGF results in 
both increased HIF-1α expression (236) and Stat3 activation (237). Because we had 
observed that silencing Stat3 prevented the induction of HIF-1α by Heregulin and IL-6,  
  
 
 
 
 
 
 
 
 
 
FIGURE 10. Heregulin increases both Stat3 binding and HIF-1α protein in MCF-7 
breast cancer cells. MCF-7 cells (1.5 x 10P
6
P) were cultured for 20h in serum free media 
followed by treatment with heregulin at the indicated concentrations for 6h. Nuclear 
extracts (30µg) were analyzed by western blotting using the indicated antibodies. Stat3 
DNA binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).  
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FIGURE 11. Stat3 siRNA blocks heregulin induced HIF-1α expression. MCF-7 cells 
were stably-transfected with empty pSilencer/pcDNA3 or pSilencer/pcDNA3 containing 
Stat3 siRNA. Cells were serum starved for 20h followed by treatment with or without 
heregulin (100ng/ml). Nuclear extracts (30µg) (Top panel) and whole cell extracts 
(100µg) (middle panel) were analyzed by Western blotting using the indicated antibodies. 
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FIGURE 12. EGF increases both Stat3 binding and HIF-1α protein in prostate 
tumor cell line DU-145. DU-145 cells (1.5 x 10P
6
P) were cultured for 20h in serum free 
media followed by treatment with EGF at the indicated concentrations for 6h. Nuclear 
extracts (30µg) were analyzed by western blotting using the indicated antibodies. Stat3 
DNA binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).  
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we wanted to know if this was also true for EGF. To verify that EGF induced both HIF- 
1α and Stat3 expression in DU145 prostate cancer, cells were treated with various 
concentrations of EGF for 6h. Consistent with previous reports (236), treatment with 
EGF results in increased expression of HIF-1α, as well as significant activation of Stat3 
(Figure 12). To determine if knocking down Stat3 expression could prevent induction of  
HIF-1α by EGF, antisense oligonucleotide was utilized. Following transfection with 
ASO, cells were treated with EGF for 6 hours and nuclear extracts were obtained for 
Western blot analysis. Results demonstrate that transfection of cells with ASO results in 
significantly diminished levels of HIF-1α in both nontreated and EGF treated samples. 
(Figure 13). These results and those described in previous sections show that Stat3 
signaling is necessary for both basal expression of HIF-1α and for its induction by 
growth signals and cytokines. 
 
Aim II. To determine the role of Stat3 in the cellular response to hypoxia. 
 
 Stat3 is required for HIF-1α induction by hypoxia 
 
It is well documented that increased levels of HIF-1α resulting from growth 
signals are due to increased synthesis, and increased levels by hypoxia result from 
stabilization and therefore accumulation. It is also reported that both hypoxic stabilization 
and growth signal induced translation can increase HIF-1α levels in a cumulative 
manner. However, several studies indicate that blocking the PI3K/AKT pathway does not 
limit the ability of hypoxia to increase HIF-1α levels (2, 6, 113). If silencing Stat3  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13. Stat3 is required for EGF mediated HIF-1α expression. DU-145 cells 
were transiently transfected with control or Stat3 ASO, serum starved for 20h followed 
by treatment with EGF (30ng/ml) for 6h. Nuclear extracts (30ug) were analyzed by 
Western blotting using the indicated antibodies. 
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decreases HIF-1α levels only by affecting AKT, then blocking Stat3 signaling should not 
affect HIF-1α induction by hypoxia. However, if silencing Stat3 also limits HIF-1α 
induction by hypoxia, then there is likely some other mechanism also at work. Because 
we had proposed that Stat3 regulates HIF-1α via AKT, we wanted to know if blocking 
Stat3 signaling could prevent the induction of HIF-1α by hypoxia.  
Our initial experiments involving HIF-1α induction by hypoxia utilized BALB/c-
3T3 fibroblasts transformed by the oncoprotein v-Src. These cells have high levels of 
Stat3 activation as well as HIF-1α expression during normoxia (figure 14). The multiple 
bands associated with HIF-1α in this figure result from post-translational modifications. 
When they were transduced with retrovirus carrying the dominant negative Stat3D or 
empty vector MSCV, Stat3 DNA binding was almost completely ablated. Furthermore 
HIF-1α expression resulting from v-Src activity was eliminated. When these cells were 
treated with the hypoxia mimic CoCl B2B, HIF-1α expression was strongly induced in the 
MSCV control cells but not in cells expressing Stat3D (Figure 14).  
To be certain that the effects we were witnessing in mouse cells also occurred in 
human cells, we examined the role of Stat3 in the hypoxic induction of HIF-1α in A2058 
human melanoma cells. Stat3 is constitutively activated in these cells due to activity of c-
Src (158). When A2058 cells were treated with inhibitors of c-Src, Stat3 activation as 
well as HIF-1α induction by hypoxia was significantly reduced (Figure 15). To determine 
the effects of silencing Stat3 on HIF-1α induction by hypoxia, A2058 cells stably 
expressing Stat3 siRNA were created. When these cells were exposed to either 1% OB2B or 
CoClB2B, HIF-1α induction was significantly limited in Stat3 siRNA but not in control cells  
 A B 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14. Stat3 is required for hypoxia induced HIF-1α expression in v-Src 
transformed Fibroblasts. BALB/c fibroblasts transformed with v-Src were stably 
transduced with empty vector MSCV or Stat3D.  Cells were cultured for 20h in serum 
free media followed by treatment with the hypoxia mimic CoCLB2B (125uM) for 6h. (A) 
Nuclear extracts (30ug) were analyzed by Western blotting using the indicated 
antibodies. SP-1 and β-actin are used to verify equal loading. (B) Stat3 DNA binding was 
determined by EMSA using nuclear extracts (8ug).  
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FIGURE 15. Treatment with Src inhibitors prevents HIF-1α by hypoxia. A2058 
human melanoma cells were seeded at 1.5 x 10 P
6
P approximately 24 h prior to treatment 
with inhibitors. Cell were treated with Src inhibitors in serum free media for 
approximately 18 hours, and then incubated under hypoxia in the presence of inhibitors 
for 6 hours. Nuclear extracts (30µg) were analyzed by Western blot using the indicated 
antibodies. 
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FIGURE 16. Stat3 is required for HIF-1α induction by hypoxia in A2058 melanoma 
cells. A2058 cells were stably-transfected with empty pSilencer or pSilencer-Stat3 
siRNA. Cells were serum starved for 20h followed by culture under conditions of 21% 
O B2B, 1% O B2B, or treatment with CoCL B2B (150uM). Nuclear extracts (30µg) (Top panel) and 
whole cell extracts (30µg) (middle panel) were analyzed by Western blotting using the 
indicated antibodies.  
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(Figure 16). These data clearly indicate that inhibition of Stat3 signaling prevents HIF-1α 
expression by Src as well as its induction by hypoxia.Because of the possibility that Stat3 
was directly acting on the HIF-1α promoter, levels of HIF-1α mRNA were examined. In 
BALB/c-3T3-v-Src cells, HIF-1α mRNA expression was significantly decreased 
following transduction with Stat3D (data not shown). However, examination of HIF-1α 
mRNA in A2058 human melanoma showed no difference in RNA expression, or possibly 
even increased levels in cells in which Stat3 had been silenced (Figure 17). Because it has 
been reported that Src may regulate HIF-1α at the level of mRNA in non-human cells but 
not in human cells (109), and our findings seemed to corroborate these reports, we did 
not investigate these results further. We conclude that at least in A2058 human melanoma 
cells, regulation of HIF-1α protein by Stat3 cannot be accounted for by changes in 
mRNA. 
 
Stat3 is required for the hypoxic induction of VEGF and MMP-2 
 
 The evidence that Stat3 is an important regulator of angiogenesis is continuously 
increasing. Several reports have indicated that Stat3 is required for VEGF production, 
both at the basal level in various cancer cells (159, 214) as well as for its induction by IL-
6 (215). Furthermore, recent reports have indicated that Stat3 regulates MMP-2 (223) and 
MMP-9 (41), both of which are important for the reorganization of the extracellular 
matrix during angiogenesis (149). The metalloproteinase genes are potentially regulated  
  
  
 
 
 
 
 
FIGURE 17. HIF-1α mRNA in A2058 melanoma treated with CoCl2. A2058 cells 
were stably-transfected with empty pSilencer or pSilencer-Stat3 siRNA. Cells were 
serum starved for 20h followed by treatment with CoCLB2B (125uM) for the indicated 
times. Total RNA (15ug) was isolated and analyzed by Northern blotting using a HIF-1α 
cDNA probe. A photograph of the ethidium bromide-stained gel verifies equal loading as 
demonstrated by the 18S and 28S rRNA bands.  
 
 
 57
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 18. Stat3 is required for VEGF induction by CoCl B2B in A2058 melanoma. 
A2058 cells stably expressing Stat3 siRNA were exposed to CoClB2B for 48 hours in serum 
free media. Whole cell extracts (100ug) were analyzed by Western blotting using the 
indicated antibodies. 
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by HIF-1α, as they have been shown to be inducible by hypoxia (128). However, it is not 
known if Stat3 is required for the hypoxic induction of these genes.  
 To examine Stat3 regulation of VEGF in response to hypoxia, A2058 cells stably 
transfected with Stat3 siRNA were utilized. These cells were treated with the hypoxia  
mimic CoCl B2B for 48h prior to harvest of whole cell extracts and western blot analysis 
(Figure 18). The long timepoint was utilized in order to obtain maximum VEGF 
induction. VEGF was induced significantly in control cells, but not in cells expressing  
Stat3 siRNA. These results not only reinforce the importance of Stat3 in VEGF 
production, but also for VEGF induction by hypoxia.  
  BALB/c-3T3 fibroblasts transformed with v-Src were used to study the role of 
Stat3 in the hypoxic regulation of MMP-2. These cells were treated with 0.1% O B2B or 
CoClB2 Bfor 24 h followed western blot analysis of whole cell extracts (Figure 19). It can be 
seen that both hypoxia and the hypoxia mimic resulted in induction of MMP-2 in MSCV 
control cells. However, in cells stably transduced with the dominant negative Stat3D, 
MMP-2 induction was prevented. Although it has been reported that Stat3 is necessary 
for MMP-2 expression, the requirement for its induction by hypoxia had not been 
demonstrated. 
 
Stat3 is activated by hypoxia 
 
Hypoxia results in increased expression of genes important for angiogenesis, and 
this increase in gene transcription is dependent on the activation of a limited set of 
transcription factors. The best documented transcription factor to be activated by hypoxia  
  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 19. Stat3 is required for MMP-2 induction by hypoxia in Fibroblasts 
transformed with v-Src. BALB/c-3T3 fibroblasts transformed with v-Src were 
transduced with dominant negative Stat3D or control MSCV. Cells were exposed to 0.1% 
O B2B or CoCl B2B for 24h hours in serum free media. Whole cell extracts (100ug) were 
analyzed by Western blotting using the indicated antibodies. 
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FIGURE 20. Stat3 is activated in human cancer cells exposed to  hypoxia. DU145 
cells (1.5 x 10 P
6
P) were incubated under 21% or 1% O B2B in serum free media. Nuclear 
extracts (30ug) were analyzed by Western blotting using the indicated antibodies. Stat3 
DNA binding was determined by EMSA using nuclear extracts (8ug) (bottom panel).  
 
 61
 62
is HIF-1. Very recently, there was a report of increased Stat3 phosphorylation following 
treatment with CoClB2 Bin a pancreatic and a prostate cancer cell line (82). Since it is known 
that Stat3 directly regulates the VEGF promoter as well as other hypoxia inducible genes, 
we wanted to determine if Stat3 was activated by hypoxia.  
To examine Stat3 activation by hypoxia, DU145 prostate cancer cells were 
exposed to 1% O B2B for 24 hours, then nuclear extracts were collected and EMSA was 
performed (Figure 20). A significant increase in Stat3 DNA binding was observed. To  
understand this activation in more detail, we wanted to determine the time course of Stat3 
activation. Because we could not be certain that O B2B concentrations were equal between 
multiple chambers, the hypoxia mimic CoCl B2B was utilized instead. When BALB/c-3T3 
fibroblasts were treated with CoClB2 Bfor various time points, significant Stat3 activation 
was seen as soon as 1 hour (Figure 21).  Next we examined the time course of Stat3 
activation in DU145 human prostate cancer cells. Increased Stat3 activation was seen as 
early as 6h, and was highest at the 24h timepoint (Figure 22). At 48h there was loss of 
Stat3 activation, however many cells had died or appeared apoptotic. Because HIF-1 is 
the main transcription factor to be activated by hypoxia and to facilitate the cellular 
response, we wanted to know if Stat3 activation coincided with or followed HIF-1α 
induction. HIF-1α levels accumulate rapidly and are already visible at the earliest 
timepoint of 30 minutes, indicating that HIF-1α accumulation precedes Stat3 activation 
(Figure 22). Since both HIF-1 and Stat3 are transcriptional activators of VEGF, we next 
examined the time course of VEGF production. VEGF accumulation correlated closely 
with Stat3 activation, peaking at 24h and diminishing at 48h. Conversely, HIF-1α levels 
were still elevated at 48h despite massive cell death and diminishing VEGF production.  
  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 21. Time course of Stat3 activation in BALB/c fibroblasts treated with 
hypoxia mimic. BALB/c fibroblasts (1.5 x 10P
6
P) were treated with CoCLB2B (125uM) for 
the indicated times. Stat3 DNA binding was determined by EMSA using nuclear extracts 
(8ug). NIH3T3 fibroblasts expressing EGFR were stimulated with EGF and used as a 
marker for Stat3 and Stat1 dimers bound to labeled hSIE probe. 
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FIGURE 22. Hypoxia mimic activates Stat3 in DU145 human prostate cancer. 
DU145 cells (1.5 x 10 P
6
P) were treated with CoCLB2B (150uM) for the indicated times in 
serum-free media. Nuclear extracts (30µg)  (Top panel) and whole cell extracts (100µg) 
(middle panel) were analyzed by Western blotting using the indicated antibodies. HIF-1β 
and β-actin are used to verify equal loading. Stat3 DNA binding was determined by 
EMSA using nuclear extracts (8ug) (bottom panel). NIH3T3 fibroblasts expressing 
EGFR were stimulated with EGF and used as a marker for Stat3 and Stat1 dimers bound 
to labeled hSIE probe. 
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From these data it is apparent that Stat3 is activated by hypoxia, and this activation 
follows and may result from HIF-1α accumulation. 
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DISCUSSION 
 
The data in this dissertation confirms and expands the role of Stat3 in 
angiogenesis. It is shown for the first time that Stat3 is required for HIF-1α expression 
resulting from a variety of growth signals in multiple cell lines. In addition, it is 
demonstrated that Stat3 is required for the hypoxic induction of HIF-1α and several 
hypoxia inducible genes. Furthermore, activation of Stat3 by hypoxia suggests 
importance in the cellular response to hypoxia. Overall, these data firmly establish Stat3 
as an extremely important regulator of angiogenesis, through the combined regulation of 
both VEGF and HIF-1α. 
 
Stat3 is required for HIF-1α induction by growth/oncogenic signals 
 
It is demonstrated here for the first time that stimulation with IL-6 results in 
increased expression of HIF-1α. MCF-7 breast cancer cells were treated with IL-6 for six 
hours in serum free media, followed by western blot analysis of nuclear extracts. 
Although HIF-1α induction by IL-6 is modest when compared to its induction by 
hypoxia, it is significant when compared to that seen by other well documented growth 
signals (133) Elevated HIF-1α levels following treatment with IL-6 did not result from 
increased transcription as verified by Northern blotting. These data show that IL-6 can be 
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added to the long list of cytokines and growth signals capable of increasing HIF-1α 
expression during normoxia. 
Since the majority of reports indicate that increased production of HIF-1α by 
growth signals results from an elevated rate of protein synthesis, we wanted to determine 
if this was also true for IL-6. To achieve this, cyclohexamide was added to MCF-7 cells 
for various times following treatment with IL-6 for 6 hours. If increased HIF-1α 
expression was due to cessation of degradation, the addition of cyclohexamide would 
have no effect as protein levels would remain high over time. If the effect of IL-6 was to 
increase the rate of protein synthesis, it would be counteracted by the addition of 
cyclohexamide and HIF-1α levels would quickly return to that of baseline. Since HIF-1α 
levels returned to that of cells not treated with IL-6 within one hour, it was concluded that 
the effect of IL-6 on HIF-1α results from an increased rate of protein synthesis. 
Since Stat3 is an important effector of IL-6 signaling, we wanted to determine if it 
was required for induction of HIF-1α. To achieve this, MCF-7 cells were stably 
transfected with Stat3 siRNA, and western blot was performed following stimulation with 
IL-6. There was limited induction of HIF-1α in response to IL-6 in cells expressing Stat3 
siRNA when compared to control cells. This effect seemed to be applicable to HIF-1α 
induction by a variety of growth signals, as induction of HIF-1α by heregulin was also 
prevented in MCF-7 cells expressing Stat3 siRNA. Furthermore, HIF-1α induction by 
EGF was prevented in DU145 cells treated with Stat3 antisense oligonucleotide. These 
findings demonstrate that Stat3 is required for HIF-1α induction by a variety of growth 
signals. 
 68
In addition to a requirement for Stat3 in the induction of HIF-1α by growth 
signals, we observed loss of basal level expression of HIF-1α when Stat3 was silenced. 
Both of these cell lines, MCF-7 breast cancer and DU-145 prostate cancer cells, have low 
but detectable basal levels of HIF-1α expression during normoxia. Although Stat3 
activation is weak when cultured in serum free media, silencing Stat3 clearly affected 
basal level HIF-1α expression. As constitutive HIF-1α expression often occurs in various 
cancers during normoxia, Stat3 is also required for this constitutive expression at least in 
these cell lines. 
It is well established that increased expression of HIF-1α occurs via activation of 
the PI3K/AKT pathway. Since it is known that the PI3K/AKT pathway is activated in 
response to IL-6 (88), the effects of treatment with IL-6 on HIF-1α induction were not 
entirely surprising. Because we were aware of the work of Dr. Chen’s research, we knew 
that there was a possible role for Stat3 in the regulation of Akt1 at the transcriptional 
level. To verify that this was occurring in our system, protein levels of Akt1 were 
determined following silencing of Stat3 in MCF-7 cells. As was expected, total levels of 
Akt1 were reduced in Stat3 siRNA cells relative to the control. In addition, 
phosphorylated levels of Akt1 and Akt2 were also abolished. In accordance with 
published data demonstrating a requirement for Akt in HIF-1α expression, we conclude 
that the likely mechanism for Stat3 mediated IL-6 induction of HIF-1α is through 
regulation of Akt.  
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Stat3 is required for VEGF induction by growth/oncogenic signals 
 
In addition to its effects on HIF-1α, it is shown here that blocking Stat3 signaling 
prevents induction of VEGF by multiple growth signals. It has previously been 
demonstrated that Stat3 is required for constitutive VEGF expression in several cancer 
cell lines, and for expression resulting from transformation with the v-Src oncogene (159, 
214). Furthermore, it has been shown that Stat3 is required for VEGF induction by IL-6 
(215). We elaborate on these findings by presenting data showing that Stat3 is essential 
for VEGF induction by heregulin and EGF.  Furthermore, Stat3 is necessary for basal 
level VEGF production in MCF-7 breast cancer cells. These results firmly establish the 
requirement for Stat3 in expression of VEGF in multiple cell lines, both at the basal level 
and for its induction by various growth factors and soluble signals. 
It has been reported that inhibition of Stat3 but not PI3K/Akt prevents the 
induction of VEGF by IL-6 (215). Since the only known mechanism of Akt regulation of 
VEGF is through HIF-1, this finding emphasizes the importance of Stat3 as a direct 
transcriptional regulator of VEGF. Although it is well documented that HIF-1 is an 
important regulator of the VEGF gene, Stat3 is probably more important at least for some 
inducers. 
Because several reports have shown that Stat3 regulates VEGF production by 
directly binding to its promoter (159, 214), it is likely that the effects we are witnessing 
on VEGF production are both direct and indirect. First, by blocking Stat3 signaling, we 
are directly downregulating VEGF production by decreasing availability of one of its 
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transcriptional activators. Second, we are decreasing availability of another critical 
transcriptional activator, HIF-1α. This idea of Stat3 as a dual regulator is consistent with 
the dramatic decreases in VEGF levels that we are witnessing, as levels of VEGF are 
entirely eliminated when Stat3 is blocked. However, in many of these same experiments 
HIF-1α induction is only partially prevented. So it is likely that the dramatic decreases in 
VEGF observed following silencing Stat3 results from the combined effect of loss of 
Stat3 as well as HIF-1α.  
 
Stat3 is required for HIF-1α induction by hypoxia 
 
Induction of HIF-1α by hypoxia has been extensively studied and is well 
characterized. Under conditions of normal oxygen, HIF-1α is rapidly and continuously 
degraded. When O B2B becomes limiting, HIF-1α is stabilized and protein rapidly 
accumulates. This process occurs independently from the increased rate of synthesis that 
occurs due to PI3K/AKT activation. Both increased synthesis and decreased degradation 
can coordinately increase HIF-1α levels in an additive manner. However, there are 
conflicting reports concerning whether or not the PI3K/AKT pathway is required for the 
hypoxic induction of HIF-1α. Several groups have shown that inhibition of PI3K with 
chemical inhibitors or dominant negative forms could prevent HIF induction by hypoxia 
(27, 91, 236). Furthermore, it has been reported that overexpression of PTEN, a negative 
regulator of PI3K, prevented the hypoxic induction of HIF-1α (238). However, other 
reports indicate that HIF-1α induction by hypoxia is not prevented by genetic inhibition 
of PI3K/AKT pathway or by treatment with chemical inhibitors (2, 6, 8, 113). 
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Importantly, chemical inhibition of PI3K prevented AKT activation while simultaneously 
having no effect on the hypoxic induction of HIF-1α (2, 8). These reports make a 
convincing argument that AKT is not required for the induction of HIF-1α by hypoxia. 
Since we had observed loss of AKT expression following silencing of Stat3, we 
concluded that this accounts for decreased HIF-1α expression following stimulation with 
IL-6 or growth signals. However, decreased AKT expression should not prevent HIF-1α 
induction by hypoxia. Therefore, if silencing Stat3 also prevented HIF-1α induction by 
hypoxia, it is likely that some other mechanism is responsible. 
  To determine if Stat3 is necessary for HIF-1α induction by hypoxia, 3T3 
fibroblasts expressing v-Src were transduced with Stat3D. Following treatment with 
CoClB2B, HIF-1α induction was prevented in cells expressing Stat3D. We next examined 
HIF-1α induction in A2058 human melanoma cells, which have constitutively activated 
c-Src (158). When these cells were treated with Src inhibitors, the hypoxic induction of 
HIF-1α was prevented. These findings verify published reports indicating that c-Src is 
necessary for HIF-1α induction by hypoxia (82). When these same cells were stably 
transfected with Stat3 siRNA, HIF-1α induction by hypoxia was prevented. These data 
demonstrate that Stat3 is required for HIF-1α induction by hypoxia in both 3T3 
fibroblasts expressing v-Src and A2058 human melanoma. 
These findings suggest that the effect of Stat3 on HIF-1α is not entirely due to the 
ability of Stat3 to regulate AKT expression. This reasoning is underscored by the fact that 
we continuously witness decreased basal level expression of HIF-1α when Stat3 is 
silenced or blocked with Stat3D. Although Stat3 clearly regulates AKT expression and 
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this will affect HIF-1α induction by growth/oncogenic signaling pathways, it is likely 
that Stat3 influences HIF-1α by some additional mechanism. Two other potential ways 
that Stat3 could regulate HIF-1α expression are via transcriptional control and/or control 
over its rate of degradation. 
 To determine if blocking Stat3 signaling affected levels of HIF-1α mRNA, 
Northern blotting was performed. In Balb/c-3T3 fibroblasts transformed with v-Src, there 
was decreased levels of HIF-1α RNA when these cell were transduced with Stat3D. This 
was not entirely surprising, as it had been reported that v-Src transformation resulted in 
increased HIF-1α mRNA levels in rat fibroblasts (109). However, in human cells 
transfected with activated c-Src there was elevated HIF-1α protein without a concurrent 
increase in mRNA (116). When we examined mRNA levels in A2058 human melanoma 
cells, silencing Stat3 did not reduce HIF-1α mRNA. Surprisingly, there appeared to be 
slightly elevated levels of RNA in Stat3 siRNA cells. Regardless, RNA could not account 
for the effects we were witnessing at the protein level in the human cells. Since these 
results seemed to comply with previously published findings, we concluded that mRNA 
regulation plays no role in Stat3 control of HIF-1α expression, at least in A2058 human 
melanoma. 
Since we had eliminated transcriptional regulation as a potential mechanism in 
A2058 cells, we investigated the possibility that Stat3 regulates HIF-1α stability. 
Previous work in Dr. Yu’s lab demonstrated reciprocal regulation of p53 by Stat3. 
Because it has been shown that silencing p53 results in stabilization of HIF-1α during 
normoxia (167), we investigated this as another potential mechanism for Stat3 regulation 
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of HIF-1α. When Stat3 was silenced in A2058 melanoma cells, we observed increased 
p53 expression and decreased HIF-1α expression during hypoxia. If the effects of Stat3 
on HIF-1α were through p53, we theorized that loss of p53 would abolish Stat3 control 
of HIF-1α. However, when we silenced p53 in these cells we observed no change in HIF-
1α levels, either during normoxia or hypoxia. Therefore, p53 was eliminated as a 
potential mechanism, at least in this cell line. 
 Another potential mechanism for Stat3 regulation of HIF-1α degradation 
concerns PHD enzymes and prolyl hydroxylation. It has been reported that in cells 
transformed with v-Src and RasV12 oncogenes, there was HIF-1α stabilization during 
normoxia and loss of hydroxylated proline residue 564 (26). Since loss of prolyl 
hydroxylation should theoretically only occur as oxygen levels decrease, the authors 
attributed this to oncogenic downregulation of prolyl hydroxylase enzyme or activity. 
They also reported that transfection with a constitutively activated version of AKT 
resulted in increased HIF-1α expression without loss of hydroxylation, suggesting that 
this second mode of oncogenic regulation of HIF-1α occurs independently of AKT. This 
idea of an additional mode of oncogenic regulation of HIF-1α is consistent with our 
findings, and it seems likely that Stat3 influences HIF-1α levels both through increased 
synthesis via PI3K/AKT and by influencing hypoxia regulated degradation. Because 
PHD-2 is the enzyme primarily responsible for hydroxylation of HIF-1α prolyl residues 
(4), and results in stabilization HIF-1α when silenced, we wanted to determine if it was 
regulated by Stat3. The idea is that silencing Stat3 will result in elevated levels of PHD-2, 
which in turn will increase HIF-1α degradation. However, we observed no change in 
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levels of PHD-2 when Stat3 was silenced in A2058 cells or when fibroblasts were 
transduced with Stat3D. The authors of the original study made use of an antibody 
specific for the hydroxylated form of HIF-1α, to which we did not have access. Through 
the use of this antibody it would be possible to further study the role of prolyl 
hydroxylation in Stat3 regulation of HIF-1α. 
The requirement for Stat3 in the hypoxic induction of HIF-1α we observed 
occurred in cell lines expressing v-Src or those that had activated c-Src. However, we did 
not examine the hypoxic regulation of HIF-1α in other cell lines. It has recently been 
reported that both Stat3 and HIF-1 are required for VEGF expression in response to Src 
activation or hypoxia (82). They suggest that Src, Stat3, and HIF-1 cooperatively induce 
VEGF expression in response to hypoxia. These findings are not entirely surprising, 
because Src is required for the hypoxic expression of both VEGF (155) and HIF-1α (82). 
Furthermore, Src is activated by hypoxia (47, 156) and transfection with v-Src or 
activated c-Src increases HIF-1α levels (109, 116) as well as activating Stat3(228). It is 
possible that Src is a key player in the hypoxic response and cooperatively utilizes HIF-
1α and Stat3 to facilitate that response. 
 
Stat3 is required for induction of several hypoxia inducible genes 
 
To further study the role of Stat3 as a facilitator of angiogenesis, we wanted to 
determine if Stat3 was required for the hypoxic induction of several hypoxia inducible 
genes. It has been reported that Stat3 is required for oncogenic expression of VEGF (159, 
214, 215). Here we demonstrate that in addition to preventing its induction by oncogenes 
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and growth signals, silencing Stat3 prevents the hypoxic induction of VEGF. This finding 
verifies a recently published report showing that Stat3 is required for the hypoxic 
induction of VEGF (82). In addition, it has been shown that Stat3 is required for 
production of the matrix metalloproteinase enzymes MMP-2 and MMP-9 (41, 223). 
These enzymes are essential for the degradation of the extracellular matrix as occurs 
during angiogenesis, and are inducible by hypoxia (128). We report here that in BALB/c-
3T3 fibroblasts transformed with the v-Src oncogene, expression of MMP-2 is 
significantly reduced in cells expressing the dominant negative Stat3D. Furthermore, 
there is induction of MMP-2 by hypoxia in control MSCV cells, but this induction is 
abolished in cells expressing Stat3D. These data demonstrate that Stat3 is required for the 
hypoxic induction VEGF and MMP-2. Since it has been demonstrated that Stat3 controls 
both of these genes at the transcriptional level, it is likely that they are directly under its 
control. However, they are also under transcriptional control by HIF-1α. Since we report 
here that Stat3 is necessary for HIF-1α expression, blocking Stat3 likely results in their 
inhibition both directly and indirectly through HIF-1α. 
 
Stat3 is activated by hypoxia 
 
The manner by which HIF-1α is activated by hypoxia is beginning to be well 
understood. Briefly, HIF-1α is hydroxylated by the PHD enzymes only in the presence of 
oxygen. VHL binds to hydroxylated HIF-1α and facilitates its degradation. As O B2 Blevels 
decrease, HIF-1α is no longer hydroxylated, interaction with VHL is impeded and 
degradation ceases. Although HIF-1α activation by hypoxia is well characterized, 
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activation of growth signaling pathways by hypoxia is not clearly understood. It has been 
reported that activation of the PI3K/AKT pathway, as measured by AKT 
phosphorylation, occurs in some cell lines (2, 3, 8, 29, 238). However, hypoxic activation 
of AKT is not universal as with HIF-1α, and was not observed in other cell lines 
including breast cancers and prostate cancers (2, 13, 236). Furthermore, it has been 
reported that PI3K/AKT activation, when it did occur, followed HIF-1α activation (2). 
Concerning Stat3 activation by hypoxia, it has recently been reported that there 
are increased levels of phosphorylated Stat3 following treatment with CoClB2B. Previously, 
it had been shown that cardiotrophin-1 activates Stat3 via a gp130-dependent signaling 
pathway in response to hypoxia (92). In addition it has been reported that Stat5 is 
activated by hypoxia (114). Furthermore, it has been shown that c-Src is activated by 
hypoxia (47, 156), and this could account for increased Stat3 activation by hypoxia. 
Because Stat3 is required for expression of HIF-1α and several hypoxia inducible genes, 
we decided to investigate its activation by hypoxia in more detail. 
In DU145 prostate cancer cells, there was significant Stat3 activation following 
24h incubation in hypoxia. Because we could not measure the exact oxygen 
concentration in the hypoxia chamber, and were not certain that levels were equal 
between chambers, we could not accurately determine the time course of Stat3 activation 
using hypoxia. As an alternative, the hypoxia mimic CoCl B2B was employed. In BALB/c 
fibroblasts, there was a significant activation of Stat3 within one hour which increased up 
to 4 h. Longer time points were not examined in these cells. In DU145 human prostate 
cancer cells, there was detectable activation of Stat3 as early as 2h, and this peaked at 
24h. Stat3 activation was significantly diminished at 48h, coinciding with massive cell 
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death. In addition to detection of Stat3 activation by EMSA, both nuclear extracts and 
whole cell extracts were analyzed by western blot to determine levels of HIF-1α and 
VEGF. In contrast to Stat3 activation, HIF-1α accumulation was extremely rapid with 
detectable protein at the earliest time point of 30 minutes. HIF-1α levels increased 
steadily up to the 24h timepoint. At 48h when Stat3 signaling had diminished and cells 
were beginning to die, HIF-1α levels remained high. Expression of VEGF closely 
paralleled that of Stat3 activation, with detectable levels at 6h that peaked at 24h and 
diminished at 48h. These data emphasize the close relationship between Stat3 activation 
and VEGF expression. Although we observed hypoxic activation of Stat3 in DU145 cells, 
this was not observed in A2058 human melanoma cells. Therefore, similar to reports 
concerning AKT activation, it seems likely that Stat3 activation by hypoxia is cell type 
specific. Furthermore, Stat3 activation occurred following HIF-1α induction as reported 
for the hypoxic activation of AKT. 
The only known transcription factor reported to increase VEGF production in 
response to hypoxia is HIF-1α. However, it has recently been reported that hypoxic 
induction of VEGF occurred in the absence of HIF-1α expression (153). Furthermore, a 
tumor cell line expressing constitutively activated AKT but lacking HIF-1 was able to 
form large and well vascularized tumors (5, 142). These reports suggest that other 
transcription factors are able to stimulate VEGF production in response to hypoxia 
independently of HIF-1α. Because Stat3 is also a transcriptional activator of VEGF, and 
we observed Stat3 activation following incubation in hypoxia in both BALB/c fibroblasts 
and human prostate cancer, it should be determined if Stat3 can facilitate the hypoxic 
induction of VEGF independently of HIF-1α. Although we had found that Stat3 
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activation occurred following induction of HIF-1α, it does not necessarily mean that 
Stat3 activation is dependent on HIF-1α. It is possible that Stat3 activation occurs in the 
absence of HIF-1α but just not as rapidly. Additional experiments should be performed to 
determine if Stat3 activation and increased VEGF production occur in response to 
hypoxia following silencing of HIF-1α. If both Stat3 activation and VEGF production 
occur independently of HIF-1α, further studies may be warranted. Reporter systems 
driven by the VEGF promoter containing mutated HIF-1 and Stat3 binding sites could be 
constructed to determine the relative importance of each transcription factor for the 
hypoxic response. 
 
Stat3 as an antiangiogenic target 
 
The data in this dissertation, along with recently published reports, position Stat3 
as an important target for antiangiogenic therapy. It has been demonstrated repeatedly 
that Stat3 is a direct regulator of the VEGF gene, and is required for VEGF production in 
response to a variety of stimuli in different cell types. Furthermore, it has been shown 
that Stat3 is required for other important facilitators of angiogenesis such as MMP-2 and 
MMP-9. Importantly, it is demonstrated here that Stat3 is essential for expression of HIF-
1α, the best documented transcriptional activator of VEGF and a wide variety of other 
angiogenic and invasive genes. Therefore, blocking Stat3 not only directly prevents 
production of multiple factors essential for angiogenesis, but also blocks production of 
the best documented angiogenesis transcription factor. These results strongly suggest that 
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targeting Stat3 could completely abrogate angiogenesis by simultaneously eliminating the 
activity of its two most important transcription factors. 
For successful antiangiogenic therapy to succeed, it is necessary to have 
extremely potent angiogenesis inhibitors (12). The classes of angiogenesis inhibitors have 
been divided into ‘direct’ and ‘indirect’ based on which cells they target (118). Direct 
inhibitors are those that inhibit growth of vascular endothelial cells by targeting them 
directly. One advantage to the use of direct inhibitors is that endothelial cells are 
genetically stable, and therefore less likely to acquire drug resistance (119). Indirect 
angiogenesis inhibitors are those that target the cancer cells, generally by blocking 
expression of angiogenic proteins. Any inhibitor that could successfully act in a both 
direct and indirect manner would have greater potency and better likelihood for success. 
In addition to the requirement of Stat3 for angiogenic factor production by tumor cells, 
several reports have indicated that Stat3 is essential for vascular endothelial cell growth, 
migration, and microvascular tube formation. Stat3 is activated by and necessary for 
signaling by both the bFGF receptor and VEGFR2 (7, 42, 176). Furthermore, Stat3 is 
required for endothelial cell migration and microvascular tube formation (225). 
Therefore, any drug targeting Stat3 would be functioning simultaneously as both a 
primary and secondary angiogenesis inhibitor, and would likely have greater potency 
because of this. 
Although antiangiogenic therapy has demonstrated efficacy in some clinical trials, 
many have had limited success (12, 54, 115, 226). The inhibitors used in these trials 
targeted only individual inducers of endothelial cell growth, such as VEGF, EGFR, 
VEGFR, and HER-2/neu (118). Since there are a variety of factors involved with 
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promoting angiogenesis, targeting only one of these may not be effective. However, the 
activity of many of these pathways is dependent on a relatively limited set of 
transcription factors. Because of this, selective inactivation of a few TFs could potentially 
inactivate a large array of angiogenic factors (39). There is current work investigating the 
effect of targeting HIF-1α for anti-angiogenic therapy (180). Since we show here that 
Stat3 is necessary for both HIF-1α expression and endothelial cell growth, Stat3 may 
prove to be the better transcription factor to target for antiangiogenic therapy. 
In summary, there are multple reasons why Stat3 inhibition will likely be an 
extremely effective antiangiogenic strategy. Stat3 is required for the production of a 
variety of angiogenic factors, in response to both growth/oncogenic signaling and 
hypoxia. Furthermore, Stat3 signaling is required for expression of HIF-1α, and therefore 
its inhibition could potentially prevent expression of a large array of angiogenic and 
invasive factors. Also, any angiogenesis inhibitor capable of preventing endothelial cell 
growth in both a direct and indirect manner simultaneously would have a distinct 
advantage. Furthermore, it is well documented that Stat3 is an important facilitator of cell 
survival and growth, so blocking Stat3 could make both tumor cells and endothelial cells 
more prone to apoptosis. Finally, targeting transcription factors will likely prove more 
effective because of their role as convergence points for a multitude of angiogenic 
factors. For these reasons, drugs that inhibit Stat3 will likely be important therapeutic 
tools for antiangiogenic treatments. 
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